News – Page 4 – Alligator Bioscience

2020-05-29

Regulatory

Alligator Bioscience presents novel supportive Phase I data at ASCO for its CTLA-4 x OX40 bispecific drug candidate ATOR-1015

Lund, Sweden, May 29, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX), announces that the company today presents additional novel data ...

2020-05-05

Lund, Sweden, May 5, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX),today announces that an annual general meeting was held in the co ...

2020-04-27

Regulatory

Lund, Sweden, April 27, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX), announces that the company today presents the status of the o ...

2020-04-23

Regulatory

Stronger focus on clinical projects "The focusing of our operations protects the company’s liquidity, but is also part of our long-term ...

2020-04-20

Lund, Sweden, April 20, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announced that the company's Nomination Committee, ...

2020-04-07

Regulatory

Lund, Sweden, 7 April 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX), announced today that the company has decided to increase its fo ...

2020-04-01

Regulatory